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Background
Patient involvement is a core value of contemporary
healthcare, and an emerging component of core out-
come set (COS) methodology.
This project pilots the use of qualitative systematic
reviews of patient perspectives on outcome prioritisation
in COS development, specifically for a COS for tubercu-
losis. The fight against tuberculosis has been hampered
by the burden of treatment regimens and drug resistance,
and clinical trials are ongoing. A COS for tuberculosis
will ensure that outcome selection across trials is consis-
tent, free from selection bias and relevant to patients,
clinicians and policy-makers.
Methods
MEDLINE, EMBASE and ASSIA were searched for stu-
dies exploring patient perspectives on tuberculosis out-
comes and their value. Each search strategy included
terms for 1) qualitative research and 2) tuberculosis.
Inclusion criteria: participants of any age with a diag-
nosis of tuberculosis; direct contact or observation; any
geographical location; publication after 2003 and in
English.
Studies were appraised using the CASP checklist.
Methods for synthesis should be based on the aims of
review. Here, the aim is not model or theory generation,
but an aggregation of perspectives and experiences. The-
matic analysis was therefore used.
Findings
13 papers were identified [1-13].
Searching for studies was demanding due to inade-
quate qualitative indexing, non-meaningful titles and
poor abstracts. Data extraction was also complex, with
substantial irrelevant data.
The included studies were conducted in countries
across South America, Africa and Asia. This improved
the international relevance of the findings, though per-
spectives from Europe and North America, as well as
more socioeconomically developed areas, was lacking.
Participants ranged in age from 5 to 80, and included
an approximately equal number of men and women.
There was limited coverage of individuals who had
defaulted or failed treatment.
Many participants used indigenous knowledge in place
of biomedical knowledge, leading to difficulties in
interpretation.
Outcomes that impair physical and social functioning
are emphasised, with their importance often linked to
fear or stigma. Mortality and treatment success or fail-
ure, as well as the adverse effects of treatment, were
noted. Despite this, they are not consistently reported in
previous clinical trials. For example, a Cochrane Review
[14] into the use of rifabutin for active tuberculosis
found that only 2 of 8 RCTs reported cure and 4 of
8 reported adverse events.
No studies were designed with outcome prioritisation
in mind. The evidence was largely ‘indirect’ and ‘con-
cealed’ in the results, reflecting the lack of conceptualisa-
tion of the phenomenon (patient outcome prioritisation)
and novelty of the research area. The paucity of direct
information that explicitly explores patient perspectives
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on the prioritisation of treatment outcomes is justifica-
tion for future qualitative research.
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